Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.

Oncotarget · 2015 · PMC4673285 · PMID 26280276

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

regorafenib suggest a positive trend in overall survival compared to regorafenib alone in patients with advanced colorectal cancer (Carter C. et al.

also in 6,846 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.